HUP0300576A3 - Divided dose therapies with vascular damaging activity - Google Patents

Divided dose therapies with vascular damaging activity

Info

Publication number
HUP0300576A3
HUP0300576A3 HU0300576A HUP0300576A HUP0300576A3 HU P0300576 A3 HUP0300576 A3 HU P0300576A3 HU 0300576 A HU0300576 A HU 0300576A HU P0300576 A HUP0300576 A HU P0300576A HU P0300576 A3 HUP0300576 A3 HU P0300576A3
Authority
HU
Hungary
Prior art keywords
divided dose
vascular damaging
damaging activity
dose therapies
therapies
Prior art date
Application number
HU0300576A
Other languages
English (en)
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of HUP0300576A2 publication Critical patent/HUP0300576A2/hu
Publication of HUP0300576A3 publication Critical patent/HUP0300576A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HU0300576A 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity HUP0300576A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (2)

Publication Number Publication Date
HUP0300576A2 HUP0300576A2 (hu) 2003-07-28
HUP0300576A3 true HUP0300576A3 (en) 2005-02-28

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300576A HUP0300576A3 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Country Status (23)

Country Link
US (1) US20030055024A1 (hu)
EP (1) EP1272200B1 (hu)
JP (1) JP2003528921A (hu)
KR (1) KR20020084267A (hu)
CN (1) CN1422157A (hu)
AT (1) ATE298240T1 (hu)
AU (2) AU4258601A (hu)
BR (1) BR0109671A (hu)
CA (1) CA2402078A1 (hu)
CZ (1) CZ20023231A3 (hu)
DE (1) DE60111622T2 (hu)
EE (1) EE200200549A (hu)
ES (1) ES2243466T3 (hu)
HU (1) HUP0300576A3 (hu)
IL (1) IL151627A0 (hu)
IS (1) IS6555A (hu)
MX (1) MXPA02009603A (hu)
NO (1) NO20024683L (hu)
NZ (1) NZ534190A (hu)
PL (1) PL357282A1 (hu)
PT (1) PT1272200E (hu)
SK (1) SK13902002A3 (hu)
WO (1) WO2001074369A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
KR20060036058A (ko) * 2003-06-18 2006-04-27 앤지오젠 파마슈티칼스 리미티드 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI830078L (fi) * 1982-01-15 1983-07-16 Lilly Co Eli Askorbinsyraetrar och liknande foereningar
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
CA2078214C (en) * 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
AU5717400A (en) * 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
CZ20023231A3 (cs) 2003-01-15
CA2402078A1 (en) 2001-10-11
IS6555A (is) 2002-10-18
AU2001242586B2 (en) 2004-12-16
DE60111622D1 (de) 2005-07-28
JP2003528921A (ja) 2003-09-30
NO20024683L (no) 2002-10-15
CN1422157A (zh) 2003-06-04
BR0109671A (pt) 2003-02-04
ES2243466T3 (es) 2005-12-01
SK13902002A3 (sk) 2003-05-02
WO2001074369A1 (en) 2001-10-11
IL151627A0 (en) 2003-04-10
US20030055024A1 (en) 2003-03-20
MXPA02009603A (es) 2004-05-14
EE200200549A (et) 2004-02-16
NZ534190A (en) 2007-05-31
NO20024683D0 (no) 2002-09-30
EP1272200A1 (en) 2003-01-08
PL357282A1 (en) 2004-07-26
PT1272200E (pt) 2005-09-30
AU4258601A (en) 2001-10-15
DE60111622T2 (de) 2006-05-18
KR20020084267A (ko) 2002-11-04
ATE298240T1 (de) 2005-07-15
HUP0300576A2 (hu) 2003-07-28
EP1272200B1 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
HUP0300290A3 (en) Combination therapies with vascular damaging activity
HU0004123D0 (en) New compounds with pharmaceutical activity
GB9909064D0 (en) Therapies
GB9911863D0 (en) Therapeutic agents
GB9905010D0 (en) Therapeutic agents
GB9904786D0 (en) Therapeutic agents
IL140974A0 (en) Active prompts
GB9918912D0 (en) New stilbenes with vascular damaging activity
GB9911881D0 (en) Therapeutic agents
EP1296704A4 (en) PEPTIDES WITH PHYSIOLOGICAL ACTIVITY
IL154364A0 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
HUP0300576A3 (en) Divided dose therapies with vascular damaging activity
GB9903476D0 (en) Therapeutic agents
GB9928607D0 (en) Syringes
GB9903119D0 (en) Therapeutic agents
ZA200110046B (en) Therapeutic agents.
SI1272200T1 (en) Divided dose therapies with vascular damaging activity
GB9902881D0 (en) Therapeutic agents
GB9914743D0 (en) Therapeutic agents
GB0016585D0 (en) Syringe
DK1272199T3 (da) Kombinationsterapier med karbeskadigende aktivitet
CA85594S (en) Syringe
GB9911499D0 (en) Medicament
GB9929405D0 (en) Medicament
CA88045S (en) Drawer face

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees